tetano
Editor, Senior Moderator
NPJ Vaccines
. 2026 Jan 14.
doi: 10.1038/s41541-026-01370-7. Online ahead of print.
An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial
Carole Henry[SUP] #[/SUP][SUP] 1 [/SUP], Daniel Makrinos[SUP] #[/SUP][SUP] 1 [/SUP], Runxia Liu[SUP] 1 2 [/SUP], Maria Cavallaro[SUP] 1 3 [/SUP], Brooke Fenderson[SUP] 1 [/SUP], Yanbo Sun[SUP] 1 [/SUP], Xiaolin Chang[SUP] 1 [/SUP], Eleanor Astley[SUP] 1 4 [/SUP], Bethany Girard[SUP] 1 [/SUP], Wen-Han Yu[SUP] 1 [/SUP], Jaap Oostendorp[SUP] 1 [/SUP], Anthony DiPiazza[SUP] 1 2 [/SUP], Robert Paris[SUP] 5 [/SUP]
Affiliations
Influenza causes substantial morbidity and mortality worldwide. This randomized, open-label, phase 1 trial (ClinicalTrials.gov, NCT05397223, date of registration: May 31, 2022) compared the immunogenicity of an mRNA-based quadrivalent influenza hemagglutinin (HA) vaccine (mRNA-1010) with a licensed comparator (FLUAD) in adults aged 18-75 years. We evaluated humoral and cellular immune responses using hemagglutination inhibition assays, flow cytometry-based memory B cell (MBC) profiling, and intracellular cytokine staining for T-cell characterization. Both vaccines elicited durable hemagglutination inhibition titers and increased HA-specific MBC responses across four vaccine strains. Compared with FLUAD, mRNA-1010 induced higher frequencies of classical and activated MBCs specific to the H3 HA included in the vaccine, while inducing similar MBC responses to the other strains. mRNA-1010 and FLUAD generated strong HA-specific CD4[SUP]+[/SUP] T-cell responses; a trend toward higher CD8[SUP]+[/SUP] T-cell responses was observed in mRNA-1010 recipients compared with FLUAD recipients for two of the four strains. These findings support the potential of the mRNA platform for seasonal influenza vaccination.
. 2026 Jan 14.
doi: 10.1038/s41541-026-01370-7. Online ahead of print.
An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial
Carole Henry[SUP] #[/SUP][SUP] 1 [/SUP], Daniel Makrinos[SUP] #[/SUP][SUP] 1 [/SUP], Runxia Liu[SUP] 1 2 [/SUP], Maria Cavallaro[SUP] 1 3 [/SUP], Brooke Fenderson[SUP] 1 [/SUP], Yanbo Sun[SUP] 1 [/SUP], Xiaolin Chang[SUP] 1 [/SUP], Eleanor Astley[SUP] 1 4 [/SUP], Bethany Girard[SUP] 1 [/SUP], Wen-Han Yu[SUP] 1 [/SUP], Jaap Oostendorp[SUP] 1 [/SUP], Anthony DiPiazza[SUP] 1 2 [/SUP], Robert Paris[SUP] 5 [/SUP]
Affiliations
- PMID: 41535296
- DOI: 10.1038/s41541-026-01370-7
Influenza causes substantial morbidity and mortality worldwide. This randomized, open-label, phase 1 trial (ClinicalTrials.gov, NCT05397223, date of registration: May 31, 2022) compared the immunogenicity of an mRNA-based quadrivalent influenza hemagglutinin (HA) vaccine (mRNA-1010) with a licensed comparator (FLUAD) in adults aged 18-75 years. We evaluated humoral and cellular immune responses using hemagglutination inhibition assays, flow cytometry-based memory B cell (MBC) profiling, and intracellular cytokine staining for T-cell characterization. Both vaccines elicited durable hemagglutination inhibition titers and increased HA-specific MBC responses across four vaccine strains. Compared with FLUAD, mRNA-1010 induced higher frequencies of classical and activated MBCs specific to the H3 HA included in the vaccine, while inducing similar MBC responses to the other strains. mRNA-1010 and FLUAD generated strong HA-specific CD4[SUP]+[/SUP] T-cell responses; a trend toward higher CD8[SUP]+[/SUP] T-cell responses was observed in mRNA-1010 recipients compared with FLUAD recipients for two of the four strains. These findings support the potential of the mRNA platform for seasonal influenza vaccination.